According to Zacks, “BioLife Solutions has pioneered the next generation of preservation solutions designed to maintain the viability and health of cellular matter and tissues during freezing, transportation and storage. Based on their proprietary bio-packaging technology and a patented understanding of the mechanism of cellular damage and death, these products enable the biotechnology and medical community to address a growing problem that exists today. “
BLFS has been the topic of several other research reports. BidaskClub cut BioLife Solutions from a buy rating to a hold rating in a report on Wednesday, December 11th. Stephens began coverage on BioLife Solutions in a report on Tuesday, January 7th. They set an overweight rating and a $23.00 price objective on the stock. Maxim Group set a $26.00 price objective on BioLife Solutions and gave the company a buy rating in a report on Tuesday, September 17th. HC Wainwright reiterated a buy rating and set a $26.00 price objective (up previously from $23.00) on shares of BioLife Solutions in a report on Monday, December 16th. Finally, Oppenheimer began coverage on BioLife Solutions in a report on Wednesday, November 20th. They set an outperform rating and a $22.00 price objective on the stock. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. BioLife Solutions presently has an average rating of Buy and an average price target of $22.50.
NASDAQ:BLFS opened at $16.08 on Monday. BioLife Solutions has a fifty-two week low of $11.60 and a fifty-two week high of $22.44. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.49 and a quick ratio of 5.33. The stock has a market capitalization of $335.01 million, a PE ratio of 114.86, a price-to-earnings-growth ratio of 11.91 and a beta of 1.24. The business’s 50-day simple moving average is $16.16 and its 200-day simple moving average is $17.33.
BioLife Solutions (NASDAQ:BLFS) last released its quarterly earnings data on Tuesday, November 12th. The medical equipment provider reported $0.01 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.01. BioLife Solutions had a return on equity of 5.37% and a net margin of 46.77%. The business had revenue of $6.60 million for the quarter, compared to analysts’ expectations of $7.65 million. On average, research analysts expect that BioLife Solutions will post 0.05 earnings per share for the current year.
In related news, VP James Mathers sold 2,693 shares of BioLife Solutions stock in a transaction that occurred on Thursday, October 17th. The stock was sold at an average price of $16.42, for a total value of $44,219.06. Following the sale, the vice president now owns 19,884 shares of the company’s stock, valued at approximately $326,495.28. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Greef Roderick De sold 10,000 shares of BioLife Solutions stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $15.46, for a total value of $154,600.00. Following the completion of the sale, the chief financial officer now directly owns 35,859 shares in the company, valued at approximately $554,380.14. The disclosure for this sale can be found here. In the last three months, insiders sold 114,940 shares of company stock worth $1,832,166. 27.00% of the stock is owned by insiders.
A number of institutional investors have recently made changes to their positions in BLFS. FMR LLC acquired a new stake in BioLife Solutions in the 1st quarter valued at approximately $2,684,000. JPMorgan Chase & Co. acquired a new position in shares of BioLife Solutions during the 2nd quarter worth approximately $30,000. Charles Schwab Investment Management Inc. acquired a new position in shares of BioLife Solutions during the 2nd quarter worth approximately $283,000. Bank of New York Mellon Corp increased its position in shares of BioLife Solutions by 20.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 77,505 shares of the medical equipment provider’s stock worth $1,314,000 after purchasing an additional 13,336 shares during the last quarter. Finally, Northern Trust Corp increased its position in shares of BioLife Solutions by 9.9% during the 2nd quarter. Northern Trust Corp now owns 50,959 shares of the medical equipment provider’s stock worth $863,000 after purchasing an additional 4,600 shares during the last quarter. 50.16% of the stock is currently owned by institutional investors and hedge funds.
BioLife Solutions Company Profile
BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.
Featured Story: Correction
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.